February 24, 2014
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Study finds bevacizumab safely treats recurrent vitreous hemorrhage after vitrectomy
Researchers reported in the Journal of Retina and Vitreous Diseases that they found the use of intravitreal bevacizumab in cases of recurrent vitreous hemorrhage after vitrectomy for proliferative diabetic retinopathy to be safe and effective.
Ferenchak and colleagues reviewed the charts on eligible patients from the Illinois Retina Associates’ database that had at least 6 months of follow-up.
The abstract explained that 12 eyes of nine patients were included in the study, and none required repeat vitrectomy for recurrent vitreous hemorrhage. Mean follow-up was 22 months.
Ferenchak and fellow researchers found that intravitreal bevacizumab was a safe and effective adjunct in this series.